Function of angiostatin and its role in chronic kidney disease

doi:10.3877/cma.j.issn.2095-3216.2017.02.007

Abstract

Abstract:

The number of patients with chronic kidney disease (CKD) that develops to end-stage renal disease (ESRD) and requires renal replacement therapy is increasing year by year. Angiogenesis factors and endogenous angiogenesis inhibitors play important roles in the progression of CKD. Angiostatin is an endogenous angiogenesis inhibitor and a proteolytic product of plasminogen. Angiostatin has anti-angiogenesis and anti-inflammatory effects, which inhibits renal tubular peripheral vascular formation and slows down blood flow velocity in non-diabetic nephropathy. In the early stage of diabetic nephropathy, angiostatin exerts its therapeutic effects by inhibiting the expression of vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1). This review discussed the structure and function of angiostatin and its role in CKD in order to discover the role of angiostatin in progression of CKD.

Key words: Angiostatin, Chronic kidney disease, Angiogenesis, Anti-inflammation, Renal peritubular capillary injury

Yuanyuan Xia, Guangyan Cai. Function of angiostatin and its role in chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(02): 79-82.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2017.02.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2017/V06/I02/79

References 31

[1]	Liu ZH. Nephrology in china [J]. Nat Rev Nephrol, 2013, 9(9): 523-528.
[2]	Tanaka T, Nangaku M. Angiogenesis and hypoxia in the kidney [J]. Nat Rev Nephrol, 2013, 9(4): 211-222.
[3]	Satoh M, Kidokoro K, Ozeki M, et al. Angiostatin production increases in response to decreased nitric oxide in aging rat kidney [J]. Lab Invest, 2013, 93(3): 334-343.
[4]	O′Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994, 79(2): 315-328.
[5]	Lay AJ, Jiang XM, Daly E, et al. Plasmin reduction by phosphoglycerate kinase is a thiol-independent process [J]. J Biol Chem, 2002, 277(11): 9062-9068.
[6]	Butera D, Wind T, Lay AJ, et al. Characterization of a reduced form of plasma plasminogen as the precursor for angiostatin formation [J]. J Biol Chem, 2014, 289(5): 2992-3000.
[7]	Molema G, van Veen-Hof I, van Loenen-Weemaes AM, et al. Pharmacokinetics and whole body distribution of elastase derived angiostatin (K1-3) in rats [J]. Int J Cancer, 2001, 91(1): 1-7.
[8]	Migita T, Oda Y, Naito S, et al. The accumulation of angiostatin-like fragments in human prostate carcinoma [J]. Clin Cancer Res, 2001, 7(9): 2750-2756.
[9]	van Tilborg AA, Sweep FC, Geurts-Moespot AJ, et al. Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids [J]. Int J Oncol, 2014, 44(4): 1394-1400.
[10]	Dodd T, Wiggins L, Hutcheson R, et al. Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin [J]. Arterioscler Thromb Vasc Biol, 2013, 33(6): 1339-1349.
[11]	Oh ET, Park MT, Song MJ, et al. Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast [J]. Oncogene, 2014, 33(10): 1229-1238.
[12]	Fliedner SM, Yang C, Thompson E, et al. Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells [J]. Am J Cancer Res, 2015, 5(4): 1558-1570.
[13]	Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells [J]. J Biol Chem, 2001, 276(43): 39562-39568.
[14]	Takada Y. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis) [J]. J Biomed Biotechnol, 2012, 2012: 136302.
[15]	Moleirinho S, Guerrant W, Kissil JL. The Angiomotins--from discovery to function [J]. FEBS Lett, 2014, 588(16): 2693-2703.
[16]	Sheikh AQ, Taghian T, Hemingway B, et al. Regulation of endothelial MAPK/ERK signalling and capillary morphogenesis by low-amplitude electric field [J]. J R Soc Interface, 2013, 10(78): 20120548.
[17]	Keskin D, Keskin G, Inal A, et al. Serum angiostatin levels in patients with Behcet′s disease: does angiogenesis play a role in the pathogenesis of Behcet's disease? [J]. Acta Clin Belg, 2014, 69(4): 246-250.
[18]	Gok M, Erdem H, Gogus F, et al. Relationship of ultrasonographic findings with synovial angiogenesis modulators in different forms of knee arthritides [J]. Rheumatol Int, 2013, 33(4): 879-885.
[19]	Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation [J]. FASEB J, 2002, 16(2): 267-269.
[20]	Perri SR, Annabi B, Galipeau J. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton [J]. FASEB J, 2007, 21(14): 3928-3936.
[21]	MacMillan CJ, Doucette CD, Warford J, et al. Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3) [J]. PLoS One, 2014, 9(2): e89770.
[22]	Jen KY, Haragsim L, Laszik ZG. Kidney microvasculature in health and disease [J]. Contrib Nephrol, 2011, 169: 51-72.
[23]	Matsumoto M, Tanaka T, Yamamoto T, et al. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis [J]. J Am Soc Nephrol, 2004, 15(6): 1574-1581.
[24]	Futrakul N, Yenrudi S, Sensirivatana R, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome [J]. Ren Fail, 2000, 22(3): 329-335.
[25]	Futrakul N, Kulaputana O, Futrakul P, et al. Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuric type 2 diabetic nephropathy [J]. Ren Fail, 2011, 33(3): 312-315.
[26]	Wu T, Du Y, Han J, et al. Urinary angiostatin--a novel putative marker of renal pathology chronicity in lupus nephritis [J]. Mol Cell Proteomics, 2013, 12(5): 1170-1179.
[27]	Basile DP, Fredrich K, Weihrauch D, et al. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure [J]. Am J Physiol Renal Physiol, 2004, 286(5): F893-F902.
[28]	Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis [J]. Am J Kidney Dis, 2007, 49(2): 186-193.
[29]	Zhang K, Meng X, Li D, et al. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade [J]. Kidney Int, 2015, 87(2): 359-369.
[30]	Zhang SX, Wang JJ, Lu K, et al. Therapeutic potential of angiostatin in diabetic nephropathy [J]. J Am Soc Nephrol, 2006, 17(2): 475-486.
[31]	Alicic RZ, Tuttle KR. Novel therapies for diabetic kidney disease [J]. Adv Chronic Kidney Dis, 2014, 21(2): 121-133.

Please choose a citation manager

Content to export